U.S. Compounding Pharmacies Market (By Pharmacy Type: 503A, 503B; By Product: Oral, Liquid Preparations, Topical, Rectal, Ophthalmic, Nasal, Otic; By Sterility: Sterile, Non-Sterile; By Compounding Type: PIA, CUPM, PDA, Others; By Therapeutic Area: Hormone replacement, Pain management, Dermatology, Pediatrics, Urology, Others; By End-User: Hospitals and Clinics, Specialty Clinics, Others) - Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Compounding Pharmacies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Compounding Pharmacies Market, by Pharmacy Type, 2024-2033
8.1.1. 503A
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. 503B
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. U.S. Compounding Pharmacies Market, by Product, 2024-2033
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Liquid Preparations
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Topical
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Rectal
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Ophthalmic
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Nasal
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Otic
9.1.7.1. Market Revenue and Forecast (2021-2033)
10.1. U.S. Compounding Pharmacies Market, by Sterility, 2024-2033
10.1.1. Sterile
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Non-Sterile
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. U.S. Compounding Pharmacies Market, by Compounding Type, 2024-2033
11.1.1. Pharmaceutical Ingredient Alteration (PIA)
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Pharmaceutical Dosage Alteration (PDA)
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Others
12.1. U.S. Compounding Pharmacies Market, by Therapeutic Area, 2024-2033
12.1.1. Hormone replacement
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Pain management
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Dermatology
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. Pediatrics
12.1.4.1. Market Revenue and Forecast (2021-2033)
12.1.5. Urology
12.1.5.1. Market Revenue and Forecast (2021-2033)
12.1.6. Others
12.1.6.1. Market Revenue and Forecast (2021-2033)
13.1. U.S. Compounding Pharmacies Market, by End-User, 2024-2033
13.1.1. Hospitals and Clinics
13.1.1.1. Market Revenue and Forecast (2021-2033)
13.1.2. Specialty Clinics
13.1.2.1. Market Revenue and Forecast (2021-2033)
13.1.3. Others
13.1.3.1. Market Revenue and Forecast (2021-2033)
14.1. U.S.
14.1.1. Market Revenue and Forecast, by Pharmacy Type (2021-2033)
14.1.2. Market Revenue and Forecast, by Product (2021-2033)
14.1.3. Market Revenue and Forecast, by Sterility (2021-2033)
14.1.4. Market Revenue and Forecast, by Compounding Type (2021-2033)
14.1.5. Market Revenue and Forecast, by Therapeutic Area (2021-2033)
14.1.6. Market Revenue and Forecast, by End-User (2021-2033)
15.1. Triangle compounding pharmacy
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Fagron
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. B. Braun melsungen ag
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Fresenius kabi ag
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Pencol Compounding Pharmacy
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. US Compounding Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Avella specialty pharmacy
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Institutional pharmacy solutions, llc
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Pharmedium services llc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Vertisis custom pharmacy
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample